French Senate rejects assisted dying bill. What happens now?

The French Senate rejected a bill to regulate assisted dying by 181 votes to 122, sending it back to the National Assembly which can approve it without further Senate consent; a second reading in the Assembly is scheduled for the week of Feb. 16 with sponsors aiming for final adoption by summer 2026. The proposed law would permit adults with grave, incurable illnesses to take lethal medication (with assisted administration only when patients physically cannot self-administer), excludes severe psychiatric and some neurodegenerative conditions, and includes a conscience clause for health workers. Separately, the Senate almost unanimously approved expanded palliative care measures (307-17), and the outcome remains a politically salient issue following President Macron’s 2022 pledge.

Analysis

Market structure: Immediate winners are European palliative-care operators and large elderly-care chains that win public funding and scale (e.g., Korian KORI.PA, ORP.PA for Orpea exposure), makers of sedation/comfort generics (Sanofi SAN.PA; Teva TEVA) and staffing/homecare specialists; losers are smaller hospice players facing reimbursement competition and insurers if adverse-mortality assumptions or malpractice costs rise. The Senate’s rejection plus an almost-unanimous palliative-care law increases near-term demand for staff and capex, pressuring labor supply and pushing pricing power toward large integrated providers with negotiating leverage.

Risk assessment: Tail risks include definitive passage of assisted-dying legislation (summer 2026) that shifts product mix (higher one-off demand for lethal medications but limited volume), major malpractice/insurance repricing (+100–300 bps in provider insurance costs), or regulatory fragmentation across EU states. Timeline: immediate (days) — political noise and small FX/bond moves; short-term (weeks/months) — key National Assembly read week of 16 Feb and amendment rounds; long-term (quarters/years) — potential final adoption by summer 2026 altering structural demand for end-of-life care and drugs.

Trade implications: Favor concentrated, size-controlled exposure to large care operators and drug-makers that can supply palliative drugs and scale staffing: target asymmetric option structures and small equity positions rather than large outright bets. Use relative-value (long KORI.PA, short ORP.PA) to express consolidation/operational-discipline thesis; hedge insurer exposure (AXA.PA) with protective puts if position size >1% AUM. Time entries ahead of 16 Feb for catalysts, scale into confirmation or rejection to maintain max exposure of 2–3% per idea.

Contrarian angles: The market understates that expanded palliative funding benefits large operators via higher occupancy and reimbursed homecare — a 10–20% EBITDA uplift over 12–24 months is plausible for best-in-class operators, making current political noise a buying opportunity. Historical parallels (Netherlands, Spain) show insurer balance-sheet impacts were muted; headline risk therefore overstates long-term downside and underestimates M&A upside among fragmented providers.

Key Decisions for Investors

• Establish a 2–3% long equity position in Korian (KORI.PA) over 6–12 months to play accelerated public funding and scale benefits; target +20% upside, stop-loss -12% if share price falls 15% within 30 days after entry.
• Implement a 1% notional 3–6 month call spread on Sanofi (SAN.PA) to capture incremental demand for palliative/comfort generics if National Assembly advances the bill; roll or harvest on decisive vote week (week of 16 Feb) or if implied volatility rises >30%.
• Enter a pair trade: long KORI.PA (1.5% AUM) and short ORP.PA (1.5% AUM) to express consolidation and operational resilience; close or rebalance if spread narrows <5% or widens >25% from entry within 9 months.
• Buy a 6–12 month protective put on AXA (AXA.PA) sized 1% AUM (strike ~5–10% OTM) as insurance against adverse reserve/malpractice repricing; reevaluate after the Assembly vote (16 Feb) and again at final reading (expected by summer 2026).